Vnitr Lek 2025, 71(3):170-175 | DOI: 10.36290/vnl.2025.030

Liver steatosis and Type 2 diabetes mellitus

Jan Škrha
3. interní klinika - klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze

Development of liver steatosis and Type 2 diabetes mellitus is caused by identical pathogenic mechanisms. Actual discoveries bring narrower information on the relationship of both diseases. New nomenclature of the metabolic liver disease and recently defined subtypes of Type 2 diabetes bring new insight on both diseases and their relationship. Increasing prevalence generates the needs not only for early diagnosis but for targeted treatment as well. The way to prevention based on healthy lifestyle has been opened to be realized from the early childhood.

Keywords: Type 2 diabetes mellitus, steatotic liver disease, pathogenesis, diagnosis, treatment.

Accepted: April 28, 2025; Published: May 16, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha J. Liver steatosis and Type 2 diabetes mellitus. Vnitr Lek. 2025;71(3):170-175. doi: 10.36290/vnl.2025.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. JHEP REPORT. 2021; 3, 3. Doi10.1016/j.jhepr.2021.100261. Go to original source... Go to PubMed...
    2. Rinella ME, Neruschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology. 2023;77:1797-1835. Go to original source... Go to PubMed...
    3. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-1986. Go to original source... Go to PubMed...
    4. Šmíd V, Dvořák K. Jaterní manifestace metabolického syndromu se nyní jmenuje MASLD - aktuální pohled na nejčastější onemocnění jater současnosti. Vnitř Lék. 2024;70(1):E8-E14. https://doi.org/10.36290/vnl.2024.013. Go to original source...
    5. Cao L, An Y, Liu HY, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta‑analysis. BMC Medicine 2024; 22:101. doi.org/10.1186/s12916-024-03315-0. Go to original source... Go to PubMed...
    6. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. Go to original source... Go to PubMed...
    7. Simon TG, Roelstraete B, Khalili H, et al. Mortality in Biopsy-Confrmed Nonalcoholic Fatty Liver Disease. Gut. 2021;70(7):1375-382. Go to original source... Go to PubMed...
    8. Li Y, Yang P, Ye J, et al. Updated mechanisms of MASLD pathogenesis. Lipids in Health and Disease (2024) 23:117. doi.org/10.1186/s12944-024-02108-x Go to original source... Go to PubMed...
    9. Dong T, Li J, Liu Y, et al. Roles of immune dysregulation in MASLD. Biomedicine & Pharmacotherapy 170 (2024) 116069. Go to original source... Go to PubMed...
    10. Škrha J. Patogeneze diabetes mellitus 1. a 2. typu v roce 2011 - jednotící model poruchy glykoregulace. Vnitř Lék. 2011;57:949-953.
    11. Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diab & Endocrinol. 2018;6:361-369. Go to original source... Go to PubMed...
    12. Škrha J. Klasifikace diabetu 2022 - perspektiva moderního přístupu k diabetu. Acta medicinae. 2022;15:30-33.
    13. Martinez-Sánchez FD, Medina-Julio D, Cordova-Gallardo J, et al. Type 2 Diabetes Subtypes and Their Role in Metabolic Liver Disease and Fibrosis Progression. Med Sci Monit. 2024;30:e946016. Go to original source... Go to PubMed...
    14. Gurjar S, Bhat RA, Upadhya R, Shen RP. Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective. Lipids in Health and Disease. 2025; 24:5 doi.org/10.1186/s12944-024-02396-3. Go to original source... Go to PubMed...
    15. Kim J, Ito T, Arai T, et al. Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis. Diagnostics. 2024;14:2500. doi.org/10.3390/diagnostics14222500. Go to original source... Go to PubMed...
    16. Malandris K, Korakas E, Sarakapiona A, et al. Accuracy of Controlled Attenuation Parameter for Liver Steatosis in HighRisk Patients for MASLD Using MRIProton Density Fat Fraction as Reference Standard. Digestive Diseases and Sciences. 2024; doi.org/10.1007/ s10620-024-08799-7. Go to original source...
    17. Korc M. Pancreatic Cancer-Associated Diabetes Is an "Exosomopathy". Clin Cancer Res. 2015; 21:1508-1510. Go to original source... Go to PubMed...
    18. Kumar J, Mohsin S, Hasan M, et al. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology. 2024; 48: 102261. Go to original source... Go to PubMed...
    19. Soresi M, Giannitrapani L. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol. 2024;30(30):3541-3547. Go to original source... Go to PubMed...
    20. Kuo CC, Chuang MH, Li CH, et al. Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes. Alimentary Pharmacology & Therapeutics. 2025;0:1-12 doi.org/10.1111/apt.18502. Go to original source... Go to PubMed...
    21. Ito D, Shimizu S, Haisa A, et al. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunctionassociated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, activecontrolled trial Effect of ipragliflozin in MASLD. J Diabetes Investig. 2024;15:1220-1230. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.